174298-72-7

Upstream product

• 174298-71-6 N-[3-(tert-Butyl-diphenyl-silanyloxymethyl)-2,4-dimethyl-phenyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-N-methyl-acetamide 
• 174298-70-5 N-[3-(tert-Butyl-diphenyl-silanyloxymethyl)-2,4-dimethyl-phenyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide 
• 174298-68-1 tert-Butyl-(2,6-dimethyl-3-nitro-benzyloxy)-diphenyl-silane 
• 174298-69-2 3-amino-1-(tert-butyldiphenylsilyloxymethyl)-2,6-dimethylbenzene 
• 82617-30-9 (2,6-dimethyl-3-nitrophenyl)methyl acetate 
• 82617-29-6 2,6-dimethyl-3-nitrobenzene-1-methanol 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 62346-87-6 2,6-dimethylbenzyl acetate 
• 62285-58-9 2,6-dimethylbenzyl alcohol 

Downstream Products

• 177477-97-3 1-Hydroxymethyl-2,6-dimethyl-3-[N-[4-(methylcarbamoyl)-cinnamoylglycyl]-N-methylamino]benzene 
• 177477-98-4 1-chloromethyl-2,6-dimethyl-3-[N-[4-(methylcarbamoyl)cinnamoylglycyl]-N-methylamino]benzene 
• 174298-74-9 3-[N-[(E)-3-(6-acetylaminopyridin-3-yl)acryloylglycyl]-N-methylamino]-1-hydroxymethyl-2,6-dimethylbenzene 
• 174298-75-0 3-[N-[(E)-3-(6-acetylaminopyridin-3-yl)acryloylglycyl]-N-methylamino]-2,6-dimethylbenzyl chloride 
• 177478-40-9 3-[2,6-Dimethyl-3-[N-[4-(methylcarbamoyl)-cinnamoylglycyl]-N-methylamino]benzyloxy]-2-amino-N-methylaniline 
• 177477-46-2 4-[2,6-dimethyl-3-[N-[4-(methylcarbamoyl)cinnamoylglycyl]-N-methylamino]benzyloxy]-2-mercapto-1-methyl-1H-benzimidazole 
• 174298-73-8 3-[N-[(E)-3-(6-Acetylaminopyridin-3-yl)acryloylglycyl]-N-methylamino]-1-(tert-butyldiphenylsilyloxymethyl)-2,6-dimethylbenzene 
• 177477-96-2 4-{(E)-2-[({[3-(tert-Butyl-diphenyl-silanyloxymethyl)-2,4-dimethyl-phenyl]-methyl-carbamoyl}-methyl)-carbamoyl]-vinyl}-N-methyl-benzamide 

Relevant academic research and scientific papers

Quinoline derivatives as bradykinin agonists

PCT No. PCT/JP97/00233 Sec. 371 Date Aug. 3, 1998 Sec. 102(e) Date Aug. 3, 1998 PCT Filed Jan. 31, 1997 PCT Pub. No. WO97/28153 PCT Pub. Date Aug. 7, 1997This invention relates to a compound of formula (1) wherein R1 is halogen, etc., R2 is halogen, etc., R3 is amino substituted with substituent(s) selected from the group consisting of lower alkyl and acyl, etc., R4 is heterocyclic (lower)alkyl, R5 is lower alkyl, and A1 is lower alkylene, and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of hypertension or the like.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety

Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]- 3-halo-2-methylimidazo[1,2-α]